Symbols / IFRX Stock $1.56 -2.50% InflaRx N.V.
IFRX (Stock) Chart
About
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Stock Fundamentals
Scroll to Statements| Market Cap | 112.78M | Enterprise Value | 70.11M | Income | -45.63M | Sales | 29.33K | Book/sh | 0.68 | Cash/sh | 0.64 |
| Dividend Yield | — | Payout | 0.00% | Employees | 65 | IPO | — | P/E | — | Forward P/E | -2.06 |
| PEG | — | P/S | 3844.97 | P/B | 2.30 | P/C | — | EV/EBITDA | -1.46 | EV/Sales | 2390.28 |
| Quick Ratio | 3.69 | Current Ratio | 4.13 | Debt/Eq | 2.16 | LT Debt/Eq | — | EPS (ttm) | -0.80 | EPS next Y | -0.76 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-06 | ROA | -45.97% | ROE | -88.63% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 378.98% | Profit Margin | 0.00% | Shs Outstand | 72.29M | Shs Float | 60.01M | Short Float | 4.08% |
| Short Ratio | 7.45 | Short Interest | — | 52W High | 1.94 | 52W Low | 0.71 | Beta | 1.51 | Avg Volume | 585.23K |
| Volume | 1.03M | Target Price | $8.87 | Recom | Buy | Prev Close | $1.60 | Price | $1.56 | Change | -2.50% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-21 | reit | Guggenheim | Buy → Buy | $14 |
| 2026-03-20 | main | Guggenheim | Buy → Buy | $14 |
| 2025-12-30 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-12-03 | down | Leerink Partners | Outperform → Market Perform | $2 |
| 2025-11-10 | main | Guggenheim | Buy → Buy | $22 |
| 2025-05-29 | main | Oppenheimer | Outperform → Outperform | $3 |
| 2025-05-08 | init | Oppenheimer | — → Outperform | $6 |
| 2025-04-29 | init | Cantor Fitzgerald | — → Overweight | $10 |
| 2025-03-26 | main | Guggenheim | Buy → Buy | $10 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-01-16 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-12-20 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-09-25 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
- IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases - MSN hu, 23 Apr 2026 14
- InflaRx (IFRX) investors back board authorities, article changes and LTIP 2026 - Stock Titan hu, 23 Apr 2026 20
- InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM - TipRanks hu, 23 Apr 2026 21
- InflaRx N.V. (IFRX) Stock Mean Reversion (-1.57%) 2026-04-20 - Community Watchlist - Cổng thông tin điện tử tỉnh Tây Ninh Mon, 20 Apr 2026 15
- InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance hu, 19 Mar 2026 07
- Is InflaRx N.V. (IFRX) stock gaining bullish momentum (Parabolic) 2026-04-18 - Community Risk Signals - Cổng thông tin điện tử Tỉnh Sơn La Sat, 18 Apr 2026 05
- IFRX Reiterated by Guggenheim -- Price Target Maintained at $14 - GuruFocus ue, 21 Apr 2026 16
- Guggenheim reiterates Inflarx stock rating on AAV opportunity - Investing.com ue, 21 Apr 2026 11
- New lab data point to lower liver toxicity risk for InflaRx pill - Stock Titan hu, 09 Apr 2026 07
- Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely - Yahoo Finance Mon, 02 Feb 2026 08
- Vilobelimab Phase 3 data earns late-breaker slot at AAD 2026 meeting - Stock Titan Wed, 18 Mar 2026 07
- InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN Sun, 19 Apr 2026 23
- InflaRx says skin ulcer drug showed remission signals despite halted trial - Stock Titan Mon, 30 Mar 2026 07
- Guggenheim Maintains InflaRx N.V. (IFRX) Buy Recommendation - MSN Mon, 20 Apr 2026 03
- InflaRx (NASDAQ: IFRX) 2026 AGM to expand share pool, renew buyback - Stock Titan hu, 02 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.03
-82.31%
|
0.17
+162.79%
|
0.06
|
0.00
|
| Operating Revenue |
|
0.03
-82.31%
|
0.17
+162.79%
|
0.06
|
0.00
|
| Cost Of Revenue |
|
7.27
+119.10%
|
3.32
+523.20%
|
0.53
|
0.00
|
| Reconciled Cost Of Revenue |
|
7.24
+120.25%
|
3.29
+595.92%
|
0.47
|
0.00
|
| Gross Profit |
|
-7.24
-129.70%
|
-3.15
-571.66%
|
-0.47
|
0.00
|
| Operating Expense |
|
41.02
-17.56%
|
49.75
+12.76%
|
44.13
+36.88%
|
32.24
|
| Research And Development |
|
25.72
-27.27%
|
35.36
-13.80%
|
41.02
+9.32%
|
37.53
|
| Selling General And Administration |
|
17.56
-9.11%
|
19.33
+19.87%
|
16.12
+12.40%
|
14.34
|
| Selling And Marketing Expense |
|
2.05
-49.35%
|
4.04
+112.01%
|
1.91
|
0.00
|
| General And Administrative Expense |
|
15.52
+1.53%
|
15.29
+7.52%
|
14.22
-0.88%
|
14.34
|
| Salaries And Wages |
|
8.94
+5.55%
|
8.47
+25.63%
|
6.74
-8.61%
|
7.37
|
| Other Gand A |
|
5.65
+7.68%
|
5.25
-5.31%
|
5.54
+19.49%
|
4.64
|
| Other Operating Expenses |
|
-2.66
+50.67%
|
-5.39
+60.15%
|
-13.53
+32.89%
|
-20.16
|
| Total Expenses |
|
48.29
-9.02%
|
53.07
+18.84%
|
44.66
+38.53%
|
32.24
|
| Operating Income |
|
-48.26
+8.79%
|
-52.91
-18.64%
|
-44.59
-38.33%
|
-32.24
|
| Total Operating Income As Reported |
|
-48.26
+8.96%
|
-53.01
-18.04%
|
-44.91
-39.30%
|
-32.24
|
| EBITDA |
|
-45.16
+0.86%
|
-45.55
-8.30%
|
-42.06
-45.84%
|
-28.84
|
| Normalized EBITDA |
|
-40.31
+18.11%
|
-49.22
-22.38%
|
-40.22
-28.57%
|
-31.29
|
| Reconciled Depreciation |
|
0.42
-13.53%
|
0.49
-14.56%
|
0.57
-4.83%
|
0.60
|
| EBIT |
|
-45.58
+0.99%
|
-46.04
-7.99%
|
-42.63
-44.81%
|
-29.44
|
| Total Unusual Items |
|
-4.85
-232.20%
|
3.67
+299.27%
|
-1.84
-175.42%
|
2.44
|
| Total Unusual Items Excluding Goodwill |
|
-4.85
-232.20%
|
3.67
+299.27%
|
-1.84
-175.42%
|
2.44
|
| Net Income |
|
-45.63
+0.93%
|
-46.06
-7.96%
|
-42.67
-44.71%
|
-29.48
|
| Pretax Income |
|
-45.62
+0.95%
|
-46.06
-7.95%
|
-42.67
-44.71%
|
-29.48
|
| Net Non Operating Interest Income Expense |
|
7.49
+135.75%
|
3.18
-15.73%
|
3.77
+1112.12%
|
0.31
|
| Interest Expense Non Operating |
|
0.04
+89.97%
|
0.02
-42.03%
|
0.04
-21.26%
|
0.05
|
| Net Interest Income |
|
7.49
+135.75%
|
3.18
-15.73%
|
3.77
+1112.12%
|
0.31
|
| Interest Expense |
|
0.04
+89.97%
|
0.02
-42.03%
|
0.04
-21.26%
|
0.05
|
| Interest Income Non Operating |
|
1.85
-42.27%
|
3.20
-15.98%
|
3.80
+525.10%
|
0.61
|
| Interest Income |
|
1.85
-42.27%
|
3.20
-15.98%
|
3.80
+525.10%
|
0.61
|
| Other Income Expense |
|
-4.85
-232.20%
|
3.67
+299.27%
|
-1.84
-175.42%
|
2.44
|
| Gain On Sale Of Security |
|
-4.85
-232.20%
|
3.67
+299.27%
|
-1.84
-175.42%
|
2.44
|
| Tax Provision |
|
0.01
+135.42%
|
0.01
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-1.02
-232.20%
|
0.77
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-45.63
+0.93%
|
-46.06
-7.96%
|
-42.67
-44.71%
|
-29.48
|
| Net Income From Continuing Operation Net Minority Interest |
|
-45.63
+0.93%
|
-46.06
-7.96%
|
-42.67
-44.71%
|
-29.48
|
| Net Income From Continuing And Discontinued Operation |
|
-45.63
+0.93%
|
-46.06
-7.96%
|
-42.67
-44.71%
|
-29.48
|
| Net Income Continuous Operations |
|
-45.63
+0.93%
|
-46.06
-7.96%
|
-42.67
-44.71%
|
-29.48
|
| Normalized Income |
|
-41.80
+14.63%
|
-48.96
-19.93%
|
-40.83
-27.87%
|
-31.93
|
| Net Income Common Stockholders |
|
-45.63
+0.93%
|
-46.06
-7.96%
|
-42.67
-44.71%
|
-29.48
|
| Diluted EPS |
|
-0.68
+12.82%
|
-0.78
+0.00%
|
-0.78
-16.42%
|
-0.67
|
| Basic EPS |
|
-0.68
+12.82%
|
-0.78
+0.00%
|
-0.78
-16.42%
|
-0.67
|
| Basic Average Shares |
|
67.29
+14.21%
|
58.92
+7.24%
|
54.94
+24.28%
|
44.21
|
| Diluted Average Shares |
|
67.29
+14.21%
|
58.92
+7.24%
|
54.94
+24.28%
|
44.21
|
| Diluted NI Availto Com Stockholders |
|
-45.63
+0.93%
|
-46.06
-7.96%
|
-42.67
-44.71%
|
-29.48
|
| Depreciation Amortization Depletion Income Statement |
|
0.39
-13.87%
|
0.46
-10.32%
|
0.51
-3.50%
|
0.53
|
| Depreciation And Amortization In Income Statement |
|
0.39
-13.87%
|
0.46
-10.32%
|
0.51
-3.50%
|
0.53
|
| Insurance And Claims |
|
0.93
-40.74%
|
1.57
-18.84%
|
1.93
-16.98%
|
2.33
|
| Total Other Finance Cost |
|
-5.68
-5400.79%
|
-0.10
+67.03%
|
-0.31
-224.07%
|
0.25
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
55.22
-27.36%
|
76.02
-36.76%
|
120.21
+17.39%
|
102.40
|
| Current Assets |
|
53.63
-25.15%
|
71.66
-34.54%
|
109.47
+12.38%
|
97.41
|
| Cash Cash Equivalents And Short Term Investments |
|
46.46
-12.08%
|
52.84
-41.47%
|
90.27
+10.35%
|
81.81
|
| Cash And Cash Equivalents |
|
16.02
-12.81%
|
18.38
+43.92%
|
12.77
-21.50%
|
16.27
|
| Cash Equivalents |
|
14.75
+4.52%
|
14.11
+174.43%
|
5.14
+150132.35%
|
0.00
|
| Cash Financial |
|
1.28
-70.08%
|
4.27
-44.05%
|
7.63
-53.10%
|
16.26
|
| Other Short Term Investments |
|
30.44
-11.69%
|
34.46
-55.54%
|
77.50
+18.25%
|
65.54
|
| Receivables |
|
1.43
-17.69%
|
1.74
-54.23%
|
3.79
+164.76%
|
1.43
|
| Taxes Receivable |
|
1.43
-17.69%
|
1.74
-54.23%
|
3.79
+164.76%
|
1.43
|
| Inventory |
|
0.00
-100.00%
|
6.90
-39.32%
|
11.37
|
0.00
|
| Raw Materials |
|
0.00
-100.00%
|
0.08
-80.62%
|
0.42
|
0.00
|
| Work In Process |
|
0.00
-100.00%
|
6.76
-36.32%
|
10.61
|
0.00
|
| Finished Goods |
|
0.00
-100.00%
|
0.06
-82.84%
|
0.33
|
0.00
|
| Prepaid Assets |
|
3.15
-36.87%
|
4.98
+26.39%
|
3.94
-66.06%
|
11.62
|
| Other Current Assets |
|
2.60
-49.96%
|
5.20
+5463.89%
|
0.09
-96.34%
|
2.55
|
| Total Non Current Assets |
|
1.58
-63.74%
|
4.36
-59.39%
|
10.74
+115.29%
|
4.99
|
| Net PPE |
|
1.15
+13.44%
|
1.01
-25.46%
|
1.36
-17.03%
|
1.64
|
| Gross PPE |
|
4.87
+9.17%
|
4.46
+3.17%
|
4.33
+4.06%
|
4.16
|
| Accumulated Depreciation |
|
-3.72
-7.92%
|
-3.45
-16.32%
|
-2.97
-17.82%
|
-2.52
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
3.09
+15.38%
|
2.68
+0.76%
|
2.66
+3.17%
|
2.58
|
| Machinery Furniture Equipment |
|
0.24
+0.00%
|
0.24
+39.40%
|
0.17
+39.16%
|
0.13
|
| Construction In Progress |
|
—
|
—
|
0.00
|
0.00
|
| Other Properties |
|
1.54
-0.20%
|
1.54
+3.25%
|
1.49
+2.63%
|
1.45
|
| Goodwill And Other Intangible Assets |
|
0.04
-16.79%
|
0.05
-26.21%
|
0.07
-50.46%
|
0.14
|
| Other Intangible Assets |
|
0.04
-16.79%
|
0.05
-26.21%
|
0.07
-50.46%
|
0.14
|
| Investments And Advances |
|
0.24
-92.32%
|
3.09
-65.84%
|
9.05
+212.07%
|
2.90
|
| Non Current Prepaid Assets |
|
0.15
-25.97%
|
0.20
-20.61%
|
0.26
-16.49%
|
0.31
|
| Other Non Current Assets |
|
0.00
+0.00%
|
0.00
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
13.66
-6.46%
|
14.60
-17.16%
|
17.63
+25.46%
|
14.05
|
| Current Liabilities |
|
12.98
-8.36%
|
14.17
-15.90%
|
16.84
+29.31%
|
13.03
|
| Payables And Accrued Expenses |
|
5.40
-52.61%
|
11.39
-4.84%
|
11.97
+140.09%
|
4.99
|
| Payables |
|
5.40
-52.61%
|
11.39
-4.84%
|
11.97
+140.09%
|
4.99
|
| Accounts Payable |
|
5.40
-52.61%
|
11.39
-4.84%
|
11.97
+140.09%
|
4.99
|
| Current Accrued Expenses |
|
—
|
—
|
—
|
3.42
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.16
-43.61%
|
2.06
+28.26%
|
1.61
+22.67%
|
1.31
|
| Current Debt And Capital Lease Obligation |
|
0.26
-36.72%
|
0.41
+8.47%
|
0.37
+1.34%
|
0.37
|
| Current Capital Lease Obligation |
|
0.26
-36.72%
|
0.41
+8.47%
|
0.37
+1.34%
|
0.37
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
6.21
|
| Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
6.21
|
| Other Current Liabilities |
|
6.16
+1943.17%
|
0.30
-89.55%
|
2.89
+1855.02%
|
0.15
|
| Total Non Current Liabilities Net Minority Interest |
|
0.68
+55.49%
|
0.44
-44.30%
|
0.78
-23.59%
|
1.02
|
| Long Term Debt And Capital Lease Obligation |
|
0.64
+60.62%
|
0.40
-46.49%
|
0.75
-24.47%
|
0.99
|
| Long Term Capital Lease Obligation |
|
0.64
+60.62%
|
0.40
-46.49%
|
0.75
-24.47%
|
0.99
|
| Other Non Current Liabilities |
|
0.04
+0.00%
|
0.04
+0.00%
|
0.04
+0.00%
|
0.04
|
| Stockholders Equity |
|
41.56
-32.34%
|
61.42
-40.13%
|
102.58
+16.11%
|
88.35
|
| Common Stock Equity |
|
41.56
-32.34%
|
61.42
-40.13%
|
102.58
+16.11%
|
88.35
|
| Capital Stock |
|
8.68
+21.80%
|
7.12
+0.80%
|
7.07
+31.72%
|
5.36
|
| Common Stock |
|
8.68
+21.80%
|
7.12
+0.80%
|
7.07
+31.72%
|
5.36
|
| Share Issued |
|
72.29
+21.80%
|
59.35
+0.80%
|
58.88
+31.72%
|
44.70
|
| Ordinary Shares Number |
|
72.29
+21.80%
|
59.35
+0.80%
|
58.88
+31.72%
|
44.70
|
| Additional Paid In Capital |
|
354.98
+5.99%
|
334.93
+0.21%
|
334.21
+18.28%
|
282.55
|
| Retained Earnings |
|
-377.83
-13.74%
|
-332.19
-16.10%
|
-286.13
-17.53%
|
-243.46
|
| Gains Losses Not Affecting Retained Earnings |
|
48.56
+10.07%
|
44.12
+10.15%
|
40.05
+9.32%
|
36.64
|
| Other Equity Adjustments |
|
48.56
+10.07%
|
44.12
+10.15%
|
40.05
+9.32%
|
36.64
|
| Total Equity Gross Minority Interest |
|
41.56
-32.34%
|
61.42
-40.13%
|
102.58
+16.11%
|
88.35
|
| Total Capitalization |
|
41.56
-32.34%
|
61.42
-40.13%
|
102.58
+16.11%
|
88.35
|
| Working Capital |
|
40.65
-29.29%
|
57.49
-37.93%
|
92.62
+9.76%
|
84.39
|
| Invested Capital |
|
41.56
-32.34%
|
61.42
-40.13%
|
102.58
+16.11%
|
88.35
|
| Total Debt |
|
0.90
+11.53%
|
0.81
-28.12%
|
1.12
-17.44%
|
1.36
|
| Capital Lease Obligations |
|
0.90
+11.53%
|
0.81
-28.12%
|
1.12
-17.44%
|
1.36
|
| Net Tangible Assets |
|
41.51
-32.35%
|
61.37
-40.14%
|
102.51
+16.21%
|
88.21
|
| Tangible Book Value |
|
41.51
-32.35%
|
61.37
-40.14%
|
102.51
+16.21%
|
88.21
|
| Available For Sale Securities |
|
0.24
-92.32%
|
3.09
-65.84%
|
9.05
|
—
|
| Held To Maturity Securities |
|
—
|
—
|
9.05
+212.07%
|
2.90
|
| Investmentin Financial Assets |
|
0.24
-92.32%
|
3.09
-65.84%
|
9.05
+212.07%
|
2.90
|
| Other Equity Interest |
|
7.17
-3.62%
|
7.44
+0.79%
|
7.38
+1.72%
|
7.26
|
| Other Inventories |
|
—
|
—
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-35.31
+27.27%
|
-48.56
-28.41%
|
-37.81
-12.06%
|
-33.74
|
| Cash Flow From Continuing Operating Activities |
|
-35.31
+27.27%
|
-48.56
-28.41%
|
-37.81
-12.06%
|
-33.74
|
| Net Income From Continuing Operations |
|
-45.63
+0.93%
|
-46.06
-7.96%
|
-42.67
-44.71%
|
-29.48
|
| Depreciation Amortization Depletion |
|
0.42
-13.53%
|
0.49
-14.56%
|
0.57
-4.83%
|
0.60
|
| Depreciation |
|
0.40
-8.90%
|
0.44
-6.10%
|
0.47
-5.34%
|
0.50
|
| Amortization Cash Flow |
|
0.02
-62.16%
|
0.04
-56.09%
|
0.10
-2.25%
|
0.10
|
| Depreciation And Amortization |
|
0.42
-13.53%
|
0.49
-14.56%
|
0.57
-4.83%
|
0.60
|
| Amortization Of Intangibles |
|
0.02
-62.16%
|
0.04
-56.09%
|
0.10
-2.25%
|
0.10
|
| Other Non Cash Items |
|
-1.81
+74.01%
|
-6.95
-210.17%
|
-2.24
+18.62%
|
-2.75
|
| Stock Based Compensation |
|
4.44
+9.32%
|
4.07
+19.08%
|
3.41
-43.51%
|
6.04
|
| Operating Gains Losses |
|
0.70
+1991.26%
|
-0.04
-108.98%
|
0.41
+7.18%
|
0.39
|
| Gain Loss On Investment Securities |
|
-5.68
|
—
|
—
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
6.39
+17311.43%
|
-0.04
-108.98%
|
0.41
+7.18%
|
0.39
|
| Change In Working Capital |
|
4.86
+313.12%
|
-2.28
-327.04%
|
1.00
+110.27%
|
-9.77
|
| Change In Inventory |
|
6.90
+54.31%
|
4.47
+139.32%
|
-11.37
|
0.00
|
| Change In Payables And Accrued Expense |
|
-5.99
-933.36%
|
-0.58
-108.30%
|
6.99
+294.80%
|
-3.59
|
| Change In Payable |
|
-5.99
-933.36%
|
-0.58
-108.30%
|
6.99
+294.80%
|
-3.59
|
| Change In Other Working Capital |
|
-0.90
-297.93%
|
0.45
+52.90%
|
0.30
+564.70%
|
-0.06
|
| Change In Other Current Assets |
|
4.80
+218.74%
|
-4.04
-147.20%
|
8.56
+311.76%
|
-4.04
|
| Change In Other Current Liabilities |
|
0.06
+102.22%
|
-2.58
+25.55%
|
-3.47
-66.77%
|
-2.08
|
| Investing Cash Flow |
|
3.23
-93.83%
|
52.36
+395.90%
|
-17.70
-191.42%
|
19.36
|
| Cash Flow From Continuing Investing Activities |
|
3.23
-93.83%
|
52.36
+395.90%
|
-17.70
-191.42%
|
19.36
|
| Capital Expenditure |
|
-0.12
-146.83%
|
-0.05
+42.21%
|
-0.08
+50.06%
|
-0.16
|
| Net Investment Purchase And Sale |
|
3.35
-93.61%
|
52.41
+397.53%
|
-17.62
-190.24%
|
19.52
|
| Purchase Of Investment |
|
-46.10
-30.45%
|
-35.34
+66.04%
|
-104.05
-61.38%
|
-64.47
|
| Sale Of Investment |
|
49.45
-43.65%
|
87.75
+1.52%
|
86.44
+2.91%
|
84.00
|
| Net Intangibles Purchase And Sale |
|
-0.12
-146.83%
|
-0.05
+42.21%
|
-0.08
+50.06%
|
-0.16
|
| Purchase Of Intangibles |
|
-0.12
-146.83%
|
-0.05
+42.21%
|
-0.08
+50.06%
|
-0.16
|
| Net Other Investing Changes |
|
-0.00
-200.00%
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
33.32
+8521.29%
|
0.39
-99.27%
|
52.99
+2634.83%
|
1.94
|
| Cash Flow From Continuing Financing Activities |
|
33.32
+8521.29%
|
0.39
-99.27%
|
52.99
+2634.83%
|
1.94
|
| Net Issuance Payments Of Debt |
|
-0.36
+7.87%
|
-0.39
-3.78%
|
-0.37
-2.62%
|
-0.36
|
| Repayment Of Debt |
|
-0.36
+7.87%
|
-0.39
-3.78%
|
-0.37
-2.62%
|
-0.36
|
| Long Term Debt Payments |
|
-0.36
+7.87%
|
-0.39
-3.78%
|
-0.37
-2.62%
|
-0.36
|
| Net Long Term Debt Issuance |
|
-0.36
+7.87%
|
-0.39
-3.78%
|
-0.37
-2.62%
|
-0.36
|
| Net Common Stock Issuance |
|
22.90
+1985.14%
|
1.10
-98.06%
|
56.48
+2303.96%
|
2.35
|
| Proceeds From Stock Option Exercised |
|
12.92
|
0.00
-100.00%
|
0.24
|
0.00
|
| Net Other Financing Charges |
|
-2.14
-561.83%
|
-0.32
+90.37%
|
-3.36
-6940.17%
|
-0.05
|
| Changes In Cash |
|
1.24
-70.55%
|
4.19
+266.21%
|
-2.52
+79.73%
|
-12.45
|
| Effect Of Exchange Rate Changes |
|
-3.59
-353.84%
|
1.41
+245.15%
|
-0.97
-139.56%
|
2.46
|
| Beginning Cash Position |
|
18.38
+43.92%
|
12.77
-21.50%
|
16.27
-38.04%
|
26.25
|
| End Cash Position |
|
16.02
-12.81%
|
18.38
+43.92%
|
12.77
-21.50%
|
16.27
|
| Free Cash Flow |
|
-35.43
+27.10%
|
-48.60
-28.26%
|
-37.89
-11.76%
|
-33.91
|
| Common Stock Issuance |
|
22.90
+1985.14%
|
1.10
-98.06%
|
56.48
+2303.96%
|
2.35
|
| Interest Paid CFO |
|
-0.03
-63.66%
|
-0.02
+41.53%
|
-0.04
+19.85%
|
-0.04
|
| Interest Received CFO |
|
1.74
-22.51%
|
2.24
+29.49%
|
1.73
+34.58%
|
1.29
|
| Issuance Of Capital Stock |
|
22.90
+1985.14%
|
1.10
-98.06%
|
56.48
+2303.96%
|
2.35
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|